ReviewACS omega2026
Continuous-Flow Synthesis of Antiepileptic Drugs: Process Intensification, Sustainability Metrics, and Scalable Manufacturing.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current trend in antiepileptic drug (AED) development entails finding and creating safer, more effective technologies as the world continues to source AEDs, thereby creating a larger carbon footprint through the batch-process method of manufacturing AEDs, along with potential resource limitations and/or supply chain constraints on batch-manufactured products. This review will evaluate the change in AED manufacturing from the batch-process method to the continuous-flow process and the advantages associated with integrating environmentally friendly chemical methods into continuous-flow manufacturing processes to create AEDs and the new generation of AEDs with reduced waste. The review will examine examples of recent advances in continuous-flow processing of major molecules, including pregabalin, levetiracetam, lacosamide, and brivaracetam. In addition, the review will discuss the obstacles preventing a complete transition to an automated, environmentally friendly, and continuous-flow process for producing AEDs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.